Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy

NO• and beyond

Rebecca H. Ritchie, Jennifer C. Irvine, Anke C. Rosenkranz, Ruchi Patel, Igor R. Wendt, John D. Horowitz, Barbara K. Kemp-Harper

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Left ventricular hypertrophy (LVH), an increased left ventricular (LV) mass, is common to many cardiovascular disorders, initially developing as an adaptive response to maintain myocardial function. In the longer term, this LV remodelling becomes maladaptive, with progressive decline in LV contractility and diastolic function. Indeed LVH is recognised as an important blood-pressure independent predictor of cardiovascular morbidity and mortality. The clinical efficacy of current treatments for LVH is reduced, however, by their tendency to slow disease progression rather than induce its reversal, and thus the development of new therapies for LVH is paramount. The signalling molecule cyclic guanosine-3′,5′-monophosphate (cGMP), well-recognised for its role in regulating vascular tone, is now being increasingly identified as an important anti-hypertrophic mediator. This review is focused on the various means by which cGMP can be stimulated in the heart, such as via the natriuretic peptides, to exert anti-hypertrophic actions. In particular we address the limitations of traditional nitric oxide (NO•) donors in the face of the potential therapeutic advantages offered by novel alternatives; NO• siblings, ligands of the cGMP-generating enzymes, soluble (sGC) and particulate guanylyl cyclases (pGC), and phosphodiesterase inhibitors. Further impact of cGMP within the cardiovascular system is also discussed with a view to representing cGMP-based therapies as innovative pharmacotherapy, alone or concurrent with standard care, for the management of LVH.

Original languageEnglish (US)
Pages (from-to)279-300
Number of pages22
JournalPharmacology and Therapeutics
Volume124
Issue number3
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Guanosine Monophosphate
Left Ventricular Hypertrophy
Nitric Oxide
Therapeutics
Natriuretic Peptides
Investigational Therapies
Ventricular Remodeling
Phosphodiesterase Inhibitors
Nitric Oxide Donors
Guanylate Cyclase
Standard of Care
Cardiovascular System
Blood Vessels
Disease Progression
Blood Pressure
Ligands
Morbidity
Drug Therapy
Mortality
Enzymes

Keywords

  • Cardiomyocyte
  • Cyclic GMP
  • Guanylyl cyclase
  • Myocardium
  • Natriuretic peptides
  • Nitric oxide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ritchie, R. H., Irvine, J. C., Rosenkranz, A. C., Patel, R., Wendt, I. R., Horowitz, J. D., & Kemp-Harper, B. K. (2009). Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond. Pharmacology and Therapeutics, 124(3), 279-300. https://doi.org/10.1016/j.pharmthera.2009.08.001

Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy : NO• and beyond. / Ritchie, Rebecca H.; Irvine, Jennifer C.; Rosenkranz, Anke C.; Patel, Ruchi; Wendt, Igor R.; Horowitz, John D.; Kemp-Harper, Barbara K.

In: Pharmacology and Therapeutics, Vol. 124, No. 3, 01.12.2009, p. 279-300.

Research output: Contribution to journalReview article

Ritchie, RH, Irvine, JC, Rosenkranz, AC, Patel, R, Wendt, IR, Horowitz, JD & Kemp-Harper, BK 2009, 'Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond', Pharmacology and Therapeutics, vol. 124, no. 3, pp. 279-300. https://doi.org/10.1016/j.pharmthera.2009.08.001
Ritchie, Rebecca H. ; Irvine, Jennifer C. ; Rosenkranz, Anke C. ; Patel, Ruchi ; Wendt, Igor R. ; Horowitz, John D. ; Kemp-Harper, Barbara K. / Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy : NO• and beyond. In: Pharmacology and Therapeutics. 2009 ; Vol. 124, No. 3. pp. 279-300.
@article{7a05aa76e3874701b8d2613c25afb9e3,
title = "Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond",
abstract = "Left ventricular hypertrophy (LVH), an increased left ventricular (LV) mass, is common to many cardiovascular disorders, initially developing as an adaptive response to maintain myocardial function. In the longer term, this LV remodelling becomes maladaptive, with progressive decline in LV contractility and diastolic function. Indeed LVH is recognised as an important blood-pressure independent predictor of cardiovascular morbidity and mortality. The clinical efficacy of current treatments for LVH is reduced, however, by their tendency to slow disease progression rather than induce its reversal, and thus the development of new therapies for LVH is paramount. The signalling molecule cyclic guanosine-3′,5′-monophosphate (cGMP), well-recognised for its role in regulating vascular tone, is now being increasingly identified as an important anti-hypertrophic mediator. This review is focused on the various means by which cGMP can be stimulated in the heart, such as via the natriuretic peptides, to exert anti-hypertrophic actions. In particular we address the limitations of traditional nitric oxide (NO•) donors in the face of the potential therapeutic advantages offered by novel alternatives; NO• siblings, ligands of the cGMP-generating enzymes, soluble (sGC) and particulate guanylyl cyclases (pGC), and phosphodiesterase inhibitors. Further impact of cGMP within the cardiovascular system is also discussed with a view to representing cGMP-based therapies as innovative pharmacotherapy, alone or concurrent with standard care, for the management of LVH.",
keywords = "Cardiomyocyte, Cyclic GMP, Guanylyl cyclase, Myocardium, Natriuretic peptides, Nitric oxide",
author = "Ritchie, {Rebecca H.} and Irvine, {Jennifer C.} and Rosenkranz, {Anke C.} and Ruchi Patel and Wendt, {Igor R.} and Horowitz, {John D.} and Kemp-Harper, {Barbara K.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.pharmthera.2009.08.001",
language = "English (US)",
volume = "124",
pages = "279--300",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy

T2 - NO• and beyond

AU - Ritchie, Rebecca H.

AU - Irvine, Jennifer C.

AU - Rosenkranz, Anke C.

AU - Patel, Ruchi

AU - Wendt, Igor R.

AU - Horowitz, John D.

AU - Kemp-Harper, Barbara K.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Left ventricular hypertrophy (LVH), an increased left ventricular (LV) mass, is common to many cardiovascular disorders, initially developing as an adaptive response to maintain myocardial function. In the longer term, this LV remodelling becomes maladaptive, with progressive decline in LV contractility and diastolic function. Indeed LVH is recognised as an important blood-pressure independent predictor of cardiovascular morbidity and mortality. The clinical efficacy of current treatments for LVH is reduced, however, by their tendency to slow disease progression rather than induce its reversal, and thus the development of new therapies for LVH is paramount. The signalling molecule cyclic guanosine-3′,5′-monophosphate (cGMP), well-recognised for its role in regulating vascular tone, is now being increasingly identified as an important anti-hypertrophic mediator. This review is focused on the various means by which cGMP can be stimulated in the heart, such as via the natriuretic peptides, to exert anti-hypertrophic actions. In particular we address the limitations of traditional nitric oxide (NO•) donors in the face of the potential therapeutic advantages offered by novel alternatives; NO• siblings, ligands of the cGMP-generating enzymes, soluble (sGC) and particulate guanylyl cyclases (pGC), and phosphodiesterase inhibitors. Further impact of cGMP within the cardiovascular system is also discussed with a view to representing cGMP-based therapies as innovative pharmacotherapy, alone or concurrent with standard care, for the management of LVH.

AB - Left ventricular hypertrophy (LVH), an increased left ventricular (LV) mass, is common to many cardiovascular disorders, initially developing as an adaptive response to maintain myocardial function. In the longer term, this LV remodelling becomes maladaptive, with progressive decline in LV contractility and diastolic function. Indeed LVH is recognised as an important blood-pressure independent predictor of cardiovascular morbidity and mortality. The clinical efficacy of current treatments for LVH is reduced, however, by their tendency to slow disease progression rather than induce its reversal, and thus the development of new therapies for LVH is paramount. The signalling molecule cyclic guanosine-3′,5′-monophosphate (cGMP), well-recognised for its role in regulating vascular tone, is now being increasingly identified as an important anti-hypertrophic mediator. This review is focused on the various means by which cGMP can be stimulated in the heart, such as via the natriuretic peptides, to exert anti-hypertrophic actions. In particular we address the limitations of traditional nitric oxide (NO•) donors in the face of the potential therapeutic advantages offered by novel alternatives; NO• siblings, ligands of the cGMP-generating enzymes, soluble (sGC) and particulate guanylyl cyclases (pGC), and phosphodiesterase inhibitors. Further impact of cGMP within the cardiovascular system is also discussed with a view to representing cGMP-based therapies as innovative pharmacotherapy, alone or concurrent with standard care, for the management of LVH.

KW - Cardiomyocyte

KW - Cyclic GMP

KW - Guanylyl cyclase

KW - Myocardium

KW - Natriuretic peptides

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=70449718779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449718779&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2009.08.001

DO - 10.1016/j.pharmthera.2009.08.001

M3 - Review article

VL - 124

SP - 279

EP - 300

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -